Asia-Pacific Antibodies Market by product type - (Monoclonal Antibodies, Polyclonal Antibodies, Anti-body drug complexes), by Indication – (Cancer, Auto immune diseases, Infectious diseases, Cardiovascular diseases, CNS disorders, others), by End user (Hospitals/clinics, Research institute, Diagnostics laboratories), by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2018–2023)

Asia-Pacific Antibodies Market by product type - (Monoclonal Antibodies, Polyclonal Antibodies, Anti-body drug complexes), by Indication – (Cancer, Auto immune diseases, Infectious diseases, Cardiovascular diseases, CNS disorders, others), by End user (Hospitals/clinics, Research institute, Diagnostics laboratories), by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2018–2023)

ID: 1180 | Pages: 145 | April 2018 | Region: Asia Pacific


Antibodies (Ab’s) are a large, Y-shaped protein produced by differentiated B-Cells (Known as Plasma cells) that are used by the immune system to detect and neutralize pathogens such as Viruses and bacteria. Antibodies can be triggered by and directed at microorganisms, foreign proteins, or toxins.

Asia-Pacific Antibodies Market was worth $ 12.95 Billion in 2018 and estimated to reach $ 20.73 Billion by the end of 2023 with a growing potential of 9.87 %.

Major factors that are influencing the Asia-Pacific Antibodies market are rising rate of adoption to therapeutic antibodies in cost sensitive market, innovative products, growing chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. Increasing cost of treatment and side effects associated with antibodies treatment are the restraints that are affecting the growth of the market.

Based on product type, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, and Anti-body drug complexes. The monoclonal antibodies are further segmented into Murine, Chimeric, Humanized, and Human. The polyclonal antibodies are further categorized into Type I, Type II, Type III, Type IV, Type V, Type VI, Type VII, Type VIII. The Antibody-Drug Complexes are further segmented into Immunogen Technology, Seattle Genetics Technology, and Immunomedics Technology.

Based on Indication, the market is segmented into Cancer, Auto immune diseases, Infectious diseases, cardiovascular diseases, and CNS disorders, others (Inflammatory, Microbial Diseases, & Other). Based on end users, the market is segmented into Hospitals/Clinics, Research institute, Diagnostics laboratories.

Based on Application, the market is segmented into Medical, Experimental. The Experimental segment is further categorized into Western blot, ELISA, Radioimmune Assays, immunofluorescence, others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry). Based on Geography, the Asia-Pacific Antibodies market is analysed under various regions namely China, India, Japan and Australia.

Major players dominating the Asia-Pacific Antibodies market are Shimadzu corporation, Novartis AG, Pfizer Inc., ThermoFisher Scientific Inc., Eli Lilly and company, Takara Bio, Levena Bio pharma, F. Hoffmann-La Roche Ltd., Bio-Rad laboratories, Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Shimadzu Corporation (Japan)                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Takara Bio, Inc. (Japan)                         

                9.7 Levena Biopharma (China)                   

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Bio-Rad Laboratories, Inc. (U.S.)                     

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  2. Asia-Pacific Monoclonal Antibodies Market By Region, From 2018-2023 ( USD Billion )
  3. Asia-Pacific Polyclonal Antibodies Market By Region, From 2018-2023 ( USD Billion )
  4. Asia-Pacific Antibody-Drug complexes Market By Region, From 2018-2023 ( USD Billion )
  5. Asia-Pacific Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  6. Asia-Pacific Cancer Market By Region, From 2018-2023 ( USD Billion )
  7. Asia-Pacific Auto immune diseases Market By Region, From 2018-2023 ( USD Billion )
  8. Asia-Pacific infectious diseases Market By Region, From 2018-2023 ( USD Billion )
  9. Asia-Pacific Cardiovascular diseases Market By Region, From 2018-2023 ( USD Billion )
  10. Asia-Pacific CNS disorders Market By Region, From 2018-2023 ( USD Billion )
  11. Asia-Pacific Antibodies Market By End users, From 2018-2023 ( USD Billion )
  12. Asia-Pacific Hospitals Market By Region, From 2018-2023 ( USD Billion )
  13. Asia-Pacific Research institute Market By Region, From 2018-2023 ( USD Billion )
  14. Asia-Pacific Diagnostics laboratories Market By Region, From 2018-2023 ( USD Billion )
  15. Asia-Pacific Antibodies Market By Application, From 2018-2023 ( USD Billion )
  16. Asia-Pacific Medical Market By Region, From 2018-2023 ( USD Billion )
  17. Asia-Pacific Experimental Market By Region, From 2018-2023 ( USD Billion )
  18. Japan Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  19. Japan Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  20. Japan Antibodies Market By End users, From 2018-2023 ( USD Billion )
  21. Japan Antibodies Market By Application, From 2018-2023 ( USD Billion )
  22. China Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  23. China Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  24. China Antibodies Market By End users, From 2018-2023 ( USD Billion )
  25. China Antibodies Market By Application, From 2018-2023 ( USD Billion )
  26. India Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  27. India Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  28. India Antibodies Market By End users, From 2018-2023 ( USD Billion )
  29. India Antibodies Market By Application, From 2018-2023 ( USD Billion )
  30. Asia-Pacific Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  31. Asia-Pacific Murine Market By Region, From 2018-2023 ( USD Million )
  32. Asia-Pacific Chimeric Market By Region, From 2018-2023 ( USD Million )
  33. Asia-Pacific Humanized Market By Region, From 2018-2023 ( USD Million )
  34. Asia-Pacific Human Market By Region, From 2018-2023 ( USD Million )
  35. Japan Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  36. China Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  37. India Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  38. Asia-Pacific Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  39. Asia-Pacific Type I Market By Region, From 2018-2023 ( USD Million )
  40. Asia-Pacific Type II Market By Region, From 2018-2023 ( USD Million )
  41. Asia-Pacific Type III Market By Region, From 2018-2023 ( USD Million )
  42. Asia-Pacific Type IV Market By Region, From 2018-2023 ( USD Million )
  43. Asia-Pacific Type V Market By Region, From 2018-2023 ( USD Million )
  44. Asia-Pacific Type VI Market By Region, From 2018-2023 ( USD Million )
  45. Asia-Pacific Type VII Market By Region, From 2018-2023 ( USD Million )
  46. Asia-Pacific Type VIII Market By Region, From 2018-2023 ( USD Million )
  47. Japan Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  48. China Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  49. India Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  50. Asia-Pacific Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  51. Asia-Pacific Immunogen Technology Market By Region, From 2018-2023 ( USD Million )
  52. Asia-Pacific Seattle Genetics Technology Market By Region, From 2018-2023 ( USD Million )
  53. Asia-Pacific Immunomedics technology Market By Region, From 2018-2023 ( USD Million )
  54. Japan Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  55. China Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  56. India Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  57. Asia-Pacific Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  58. Asia-Pacific Western Blot Market By Region, From 2018-2023 ( USD Million )
  59. Asia-Pacific ELISA Market By Region, From 2018-2023 ( USD Million )
  60. Asia-Pacific Radioimmune Assays Market By Region, From 2018-2023 ( USD Million )
  61. Asia-Pacific immunoflourscence Market By Region, From 2018-2023 ( USD Million )
  62. Japan Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  63. China Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  64. India Antibodies Market By Experimental, From 2018-2023 ( USD Million )
Middle East And Africa Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequen...
Latin America Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequencing, Tar...
Asia-pacific Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequencing, Targ...
Europe Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequencing, Targeted G...
North America Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequencing, Tar...
Microbiome Sequencing Services Market By Technology (sequencing By Synthesis (SBS), Sequencing By Ligation (SBL), Pyrosequencing, Sanger Sequencing, And Others), By Application (shotgun Sequencing, Targeted Gene Seq...
Middle East And Africa Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Global Indu...
Latin America Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Industry Analysis, S...
Asia-Pacific Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Industry Analysis, Si...
Europe Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Industry Analysis, Size, Sh...
North America Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Industry Analysis, S...
Platelet Rich Plasma Market By Application (Orthopaedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), By Product (Pure, Leukocyte-Rich, Leukocyte-Rich Fibrin), By Region - Global Industry Analysis, Size, Sh...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.